Status:
COMPLETED
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
Lead Sponsor:
CeleCor Therapeutics
Collaborating Sponsors:
St. Antonius Hospital
Diagram B.V.
Conditions:
Coronary Disease
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. This study ...
Detailed Description
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. For patient...
Eligibility Criteria
Inclusion
- Patients with STEMI, presenting with persistent chest pain (\>30 min) and ≥1 mm ST-segment elevation in two adjacent electrocardiograph leads, with \>6 mm cumulative ST-segment deviation, in whom the total duration of symptoms to first intracoronary device deployment (excluding a wire) is anticipated to be within 6 hours
- Adult males and females 18 years of age or older
- Females must be non-pregnant, non-lactating, and of non-childbearing potential (postmenopausal or surgically sterilized) by history and review of medical record
- Weight (by history) of between 52 and 120 kg
- Written informed consent (following short-form of the informed consent form at Cardiac Catheterization Lab)
Exclusion
- High probability in the opinion of the cardiologist that current STEMI is caused by stent thrombosis and the previous PCI related to this stent thrombosis is \<1 month
- High suspicion of type II MI
- Out of hospital cardiac arrest (OHCA)
- Therapy resistant cardiogenic shock (systolic blood pressure ≤80 mm Hg for \>30 minutes)
- Persistent severe hypertension (systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg)
- Current active coronavirus disease 2019 (COVID-19) infection (criteria according to local guidelines)
- Known severe liver disease
- Known history of severe renal dysfunction (glomerular filtration rate \<30 mL/min or serum creatinine \>200 mmol/L \[\>2.5 mg/dL\])
- Known left bundle branch block
- Requirement of oral anticoagulation (Vitamin K antagonists {VKA} or direct oral antagonists {DOACs})
- Current treatment with αIIbβ3 receptor antagonist (other than RUC-4)
- Coagulation abnormality, known bleeding disorder, or history of documented prior hemorrhagic or thrombotic stroke within the past 6 months
- History of upper or lower GI bleeding within the past 6 months
- Known clinically important anemia
- Known clinically important thrombocytopenia (platelet count of less than 150,000/μL)
- Known history of allergy to any of the ingredients in the RUC-4 formulation (i.e., acetate buffer, sucrose)
- Major surgery within the past 6 months
- Life expectancy of less than 6 months
- Any clinically significant abnormality identified prior to enrollment that in the judgment of the Investigator would preclude safe completion of the study
- Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the patient's ability to comply with the study protocol
Key Trial Info
Start Date :
June 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2020
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04284995
Start Date
June 2 2020
End Date
December 14 2020
Last Update
February 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Antonius hospital
Nieuwegein, CM, Netherlands, 3435